TOP > 外国特許検索 > GLUCOSE-SENSITIVE CELL PROTECTING AGENT

GLUCOSE-SENSITIVE CELL PROTECTING AGENT UPDATE

外国特許コード F170008929
整理番号 (S2015-0924-N0)
掲載日 2017年1月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP060882
国際公開番号 WO 2016159335
国際出願日 平成28年4月1日(2016.4.1)
国際公開日 平成28年10月6日(2016.10.6)
優先権データ
  • 特願2015-077228 (2015.4.3) JP
発明の名称 (英語) GLUCOSE-SENSITIVE CELL PROTECTING AGENT UPDATE
発明の概要(英語) Provided is a means for reducing adverse effects of a high glucose concentration on the living body. Provided are: a preparation for protecting glucose-sensitive cells from glucose toxicity caused by a high glucose concentration, the preparation containing N-acetyl-D-mannosamine; a pharmaceutical composition for protecting glucose-sensitive cells from glucose toxicity caused by a high glucose concentration, the pharmaceutical composition containing an effective amount of N-acetyl-D-mannosamine and a pharmaceutically acceptable carrier; a use of N-acetyl-D-mannosamine to prepare a drug for protecting glucose-sensitive cells from glucose toxicity caused by a high glucose concentration; and a method for protecting glucose-sensitive cells from glucose toxicity caused by a high glucose concentration, the method including a step for administering an effective amount of N-acetyl-D-mannosamine to a subject in need thereof. The glucose-sensitive cells are selected from the group consisting of nerve cells, renal cells, and vascular endothelial cells.
従来技術、競合技術の概要(英語) BACKGROUND ART
As a complication of diabetes, diabetic retinopathy, diabetic nephropathy, vascular complications, skin complications, immunodeficiency, neurological disorders (neuropathy), high blood pressure and the like are known. These complications of hyperglycemia cause mechanism may not be apparent, is not an effective treatment. Further, chronic hyperglycemia, but also the cause of these diseases, central nervous system may be of use of the neurotoxic (glucose neurotoxicity) have been reported (non-patent document 1-4).
N - -D- acetyl mannosamine -D- acetyl glucosamine N- isomer is, for example, drugs or active pharmaceutical ingredient and the enzymatic synthesis of sialic acid (N - acetylneuraminic acid) is known as a raw material. In addition, mannosamine -D- N - is acetyl, and derivatives thereof, can be synthesized enzyme sialic acid derivatives and, in the industry, an important material. N - The method of manufacturing the -D- acetyl mannosamine, N- acetylglucosamine when isomerization under alkaline conditions, boric acid or boric acid salt by adding, to a molar conversion of the acetyl mannosamine N- a method for increasing the yield has been known (Patent Document 1). In addition, sialic acid as a substrate by reacting N- acetylneuraminic acid lyase, a method for producing N- acetyl mannosamine -D- also known (patent document 2). N - Acylation of mannosamine by contacting the cell with a body, to a method for modulating lectin binding to the surface of the cell or a neural cell modulating the growth of a method has been proposed (patent document 3). In Patent Document 3, is -D- acetyl mannosamine N -, it is possible to promote axon growth in vitro for are used as a negative control. Further, the primary enzyme of the biosynthesis of sialic acid -N- acetylglucosamine 2 - epimerase/N - uridine diphospho acetyl mannosamine (ManNAc) kinase (GNE/MNK) a mutation in a gene encoding GNE (example, M712T point mutations caused by mutations) is, for an adult onset autosomal recessive hereditary inclusion body myositis (HIBM) are known to cause. M712T Post-natal age of the 3 homozygous mutant mice have Gne/Mnk survive beyond not, severe glomerular-developed proteinuria is, by the administration of a repair N- acetyl mannosamine (ManNAc) has been reported (non-patent document 5) are.
The inventors of the present invention, the brain N- acetyl mannosamine -D- improvement and functional decrease in the effective for the improvement of sleep disorders are found (Patent Document 4 and 5). In addition, the present inventors have found, using N- acetyl mannosamine -D -, or pluripotent stem cells from neural progenitor cells to produce efficiently has succeeded in (Patent Document 6). Further, the present inventors, N- acetyl mannosamine -D- useful in the treatment of depression are found (Patent Document 7). Depression, onset of diabetes and diabetes by increasing the mortality rate, switched to arteriosclerosis, myocardial infarction and cerebral infarction increased risk, and also increasing the mortality due to cancer are known, the progression of the disease and depression these physiological or pathological relationship is unknown.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • THE UNIVERSITY OF TOKYO
  • 発明者(英語)
  • SHIOTA KUNIO
  • HAYAKAWA KOJI
  • TAKAMORI MITSUKO
  • FUJII RYOSUKE
  • ITO YUKISHIGE
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close